Overview

Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

Status:
Completed

Trial end date:
2013-11-01

Target enrollment:

Participant gender:

Summary

This study will investigate safety, tolerability and pharmacokinetics of ABT-354 in up to 20 male and female subjects, between 55 to 90 years of age with mild to moderate Alzheimer's disease on stable doses of acetylcholinesterase inhibitors.

Phase:

Phase 1

Details

Lead Sponsor:

AbbVie

Treatments:

Cholinesterase Inhibitors